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Highlights 
• Ca2+-entry via ICa,L is essential for the activation of ICl(Ca) 
• ICl(Ca) can be activated even in the absence of CICR 
• TMEM16A and Bestrophin-3 are expressed on human left ventricular muscle 
• TMEM16A and Bestrophin-3 co-localize with each other and with Cav1.2 channels 
• Only BAPTA but not EGTA can buffer effectively [Ca2+]cleft 
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Abstract 
Ca2+-activated Cl− current (ICl(Ca)) mediated by TMEM16A and/or Bestrophin-3 may contribute to 
cardiac arrhythmias. The true profile of ICl(Ca) during an actual ventricular action potential (AP), 
however, is poorly understood. 
We aimed to study the profile of ICl(Ca) systematically under physiological conditions (normal Ca2+ 
cycling and AP voltage-clamp) as well as in conditions designed to change [Ca2+]i. The expression of 
TMEM16A and/or Bestrophin-3 in canine and human left ventricular myocytes was examined. The 
possible spatial distribution of these proteins and their co-localization with Cav1.2 was also studied. 
The profile of ICl(Ca), identified as a 9-anthracene carboxylic acid-sensitive current under AP voltage-
clamp conditions, contained an early fast outward and a late inward component, overlapping early and 
terminal repolarizations, respectively. Both components were moderately reduced by ryanodine, while 
fully abolished by BAPTA, but not EGTA. [Ca2+]i was monitored using Fura-2-AM. Setting [Ca2+]i to 
the systolic level measured in the bulk cytoplasm (1.1 µM) decreased ICl(Ca), while application of Bay 
K8644, isoproterenol, and faster stimulation rates increased the amplitude of ICl(Ca). Ca2+-entry through 
L-type Ca2+ channels was essential for activation of ICl(Ca). TMEM16A and Bestrophin-3 showed 
strong co-localization with one another and also with Cav1.2 channels, when assessed using 
immunolabeling and confocal microscopy in both canine myocytes and human ventricular 
myocardium. 
Activation of ICl(Ca) in canine ventricular cells requires Ca2+-entry through neighboring L-type Ca2+ 
channels and is only augmented by SR Ca2+-release. Substantial activation of ICl(Ca) requires high Ca2+ 
in the dyadic clefts which can be effectively buffered by BAPTA, but not EGTA. 
 
 
Keywords: Ca2+-activated Cl− current; canine cardiomyocytes; action potential voltage-clamp; 
TMEM16A; Bestrophin-3; human cardiomyocytes 
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Abbreviations 
9-AC  9-anthracene carboxylic acid  
AP  action potential  
APVC  action potential voltage-clamp 
APD90  action potential duration at 90 % of repolarization 
BKCa  large-conductance Ca2+-activated K+ channels 
CaT  calcium transient 
Cav1.2  pore forming subunit of L-type Ca2+ channel 
[Ca2+]cleft Ca2+ concentration in the dyadic cleft 
[Ca2+]i  intracellular Ca2+ concentration in bulk cytoplasm 
[Cl−]i  intracellular Cl− concentration  
CDI  Ca2+-dependent inactivation 
CICR  Ca2+-induced Ca2+-release 
DAD  delayed afterdepolarization 
DAPI  4’,6-diamidino-2-phenylindole 
DIDS  4,4’-diisothiocyanostilbene-2,2’-disulfonic acid 
HEPES  4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid 
ISO  isoproterenol 
I9-AC  9-anthracene carboxylic acid-sensitive current 
ICa,L  L-type Ca2+ current  
ICl(Ca)  Ca2+-activated Cl− current 
IKs  slow component of delayed rectifier K+ current 
INCX  Na+/Ca2+ exchange current 
INISO  nisoldipine-sensitive current 
LTCC  L-type Ca2+ channel 
PCC  Pearson correlation coefficient 
RyR  ryanodine receptor 
SEM  Standard Error of the Mean 
SITS  4-acetamido-4'-isothiocyanostilbene-2,2'-disulfonic acid  
SR  sarcoplasmic reticulum 
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1. Introduction 
 
The role of anions in cardiac electrophysiology received far less attention as physiological and 
pharmacological research has focused mainly on cation channels [1] until the discovery of the cAMP-
activated Cl− current [2, 3]. Anion currents are still less understood regarding their molecular identity, 
physiological role and biophysical, pharmacological properties [4, 5]. Cl− channels are divided into 
four groups according to their gating properties: ligand-gated channels, voltage-gated channels, 
phosphorylation-regulated cystic fibrosis transmembrane conductance regulator channels and Ca2+-
activated Cl− channels have been identified so far [6]. 
Intracellular Ca2+ concentration ([Ca2+]i) and membrane potential are changing dynamically and 
characteristically throughout the cardiac cycle [7]. Accordingly, the actual magnitudes of these 
variables delicately guide the Ca2+-activated Cl− current (ICl(Ca)) during the ventricular action potential 
(AP). Moreover, the actual Ca2+ concentration in various regions of the cell may also be very variable. 
Ca2+ concentration in the dyadic cleft ([Ca2+]cleft) during systole is much higher than in the bulk 
cytoplasm [8]. Increase in [Ca2+]i can dramatically shift the voltage-dependence of ICl(Ca) towards more 
negative potentials [9]. Thus, the actual [Ca2+]cleft has a crucial role in setting the momentary ICl(Ca) at 
any given membrane potential. The other peculiar property of ICl(Ca), in contrast to other types of ion 
currents underlying the cardiac AP, is that it can mediate both outward (Cl− influx) and inward (Cl− 
efflux) currents because the reversal potential of Cl− lays between the resting potential and the 
overshoot potential of the AP [10]. ICl(Ca) has been characterized in the heart first in the early 1990s 
[11] as a Ca2+-activated but 4-aminopyridine insensitive component of the transient outward current 
[12] contributing to the early (phase-1) repolarization of cardiac cells [10]. 
Although a number of molecular candidates have been claimed to mediate ICl(Ca), the molecular 
identity of the channel protein still remains to be elucidated [6, 10]. Recently a new family of anion 
channels, the Bestrophins have been discovered and proposed to act as chloride channels, or at least as 
their Ca2+-sensitive subunits [13]. This field was also highlighted by the identification of TMEM16A 
(also known as Anoctamin1 or Ano1) as another putative candidate for ICl(Ca) [14-16]. Moreover, 
TMEM16A expression was described in murine ventricle and confirmed to be responsible for ICl(Ca) in 
ventricular myocytes [17]. 
According to results obtained in rabbit myocytes, activation of ICl(Ca) required Ca2+-induced Ca2+-
release (CICR) from the sarcoplasmic reticulum (SR) in addition to Ca2+-entry through the Ca2+ 
channels of the sarcolemma [11, 18, 19]. Recent publications, however, raised the possibility that 
activation of ICl(Ca) is mediated by a Ca2+ signal localized at the sarcolemma [20, 21]. Moreover, it has 
turned out that TMEM16A channels are abundantly available in close proximity to IP3 receptors in 
nociceptive neurons and to ryanodine receptors (RyRs) in smooth muscle cells [21, 22]. 
In the majority of previous studies ICl(Ca) was recorded under non physiological conditions, i.e. when 
the Ca2+ homeostasis of the myocytes was disturbed, the ionic composition was largely modified and 
rectangular voltage pulses were applied. These studies have demonstrated the existence of ICl(Ca) in 
many species, including rabbit [11, 19], sheep [23], pig [24], and dog [12], however, the role of ICl(Ca) 
during the actual AP of the studied ventricular myocyte has not been investigated so far. 
ICl(Ca) can contribute to the development of cardiac arrhythmias. ICl(Ca) may generate a component of 
the arrhythmogenic transient inward current, leading to membrane depolarization (delayed 
afterdepolarization, DAD) and triggered activity in Ca2+ overloaded cells [17, 25, 26]. On the other 
hand, blocking the Cl− conductance by 9-anthracene carboxylic acid (9-AC) was shown to increase 
arrhythmia incidence in canine ventricular cells [27]. 
Therefore the aims of our research were (1) to characterize ICl(Ca) profiles under actual cardiac APs in 
canine ventricular cardiomyocytes, in a species with cardiac APs and ion currents most resembling to 
those of human [28, 29], (2) to study the Ca2+- and rate-dependence of the current, (3) to confirm Cl− 
as the charge carrier, (4) to examine the role of transsarcolemmal Ca2+-entry and CICR in activation of 
ICl(Ca) (5) to reveal the expression pattern of Bestrophin-3 and TMEM16A and (6) to visualize their 
cellular appearance regarding co-localization with each other as well as with pore forming subunit of 
L-type Ca2+ channel (Cav1.2). 
Action potential voltage-clamp (APVC) technique was used to record ICl(Ca) profiles as 9-AC-sensitive 
current (I9-AC) [30] under various experimental conditions designed to alter intracellular calcium and 
chloride concentrations. [Ca2+]i and cell shortening were also monitored. Immunocytochemistry and 
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confocal imaging were used to detect expression and co-localization of channel proteins in both canine 
left ventricular myocytes and isolated myocytes and multicellular ventricular preparations obtained 
from non-diseased human left ventricle. Our results indicate that blockade of SR Ca2+-release may 
decrease, but fails to eliminate the activation of ICl(Ca) in canine ventricular cells confirming the critical 
importance of transsarcolemmal Ca2+-entry through L-type Ca2+ channels (LTCCs) in controlling 
ICl(Ca). TMEM16A and Bestrophin-3 showed strong co-localization with one another and also with 
Cav1.2 channels in both canine and human left ventricular myocardium. 
 
 
2. Methods 
 
Detailed description of the applied methods including electrophysiological protocols, composition of 
solutions, molecular biological reagents, etc. is provided in the Supplement. 
Human hearts were obtained from organ donors whose non-diseased hearts were explanted to obtain 
pulmonary and aortic valves for transplant surgery. The investigations conformed to the principles of 
the Declaration of Helsinki.  Experimental protocols were approved by the Ethical Review Board of 
the Medical Center of the University of Szeged and by the Scientific and Research Ethical Committee 
of the Medical Scientific Board at the Hungarian Ministry of Health (ETT-TUKEB; No. 51-57/1997 
OEj and 4991-0/2010-1018EKU [339/PI/010]). After explantation, each heart was perfused with 
cardioplegic solution and kept cold (4-6 °C) for 2-4 hours prior to dissection. Cardiac samples were 
flash-frozen in liquid nitrogen and stored at −80 °C until use. In case of studying cellular expression 
patterns of ion channel proteins single, isolated left ventricular myocytes were used for 
immunocytochemistry and confocal imaging. 
All animal handling and laboratory procedures conform to the Guide for the Care and Use of 
Laboratory Animals published by the US National Institutes of Health (NIH publication no. 85-23, 
revised 1996), and to our Institutional Animal Care and Use Committee approved protocols (license 
no. 10/2011/DEMÁB). Chemicals and reagents were purchased from Sigma-Aldrich Co. (St. Louis, 
MO, USA) if not specified otherwise. Ryanodine was obtained from Cayman Chemical Co. (Ann 
Arbor, MI, USA). All experiments except for molecular biological techniques were applied at 37 °C 
and pH = 7.4. 
Experiments were performed in canine left ventricular myocytes obtained by enzymatic dispersion 
using the segment perfusion technique [30]. Transmembrane ion currents were recorded using 
conventional whole-cell voltage clamp and action potential voltage clamp (APVC) techniques. In this 
latter case the own action potential of the myocyte, recorded previously in current clamp mode in 
control (in the absence of any drug in the perfusion solution), was played back as a command signal to 
visualize the actually flowing current profiles. ICl(Ca) was dissected using 9-AC and presented as I9-AC. 
Single cell shortening was recorded by optical edge detection, while changes in intracellular free Ca2+ 
concentration were assessed by Fura-2-AM (Molecular Probes, Eugene, OR, USA). Electrical 
stimulation was applied through the patch pipette to simultaneously record the electrical and the Ca2+ 
signals from the same cell except where otherwise stated. Immunolabeling for TMEM16A, 
Bestrophin-3 and Cav1.2 was performed in isolated canine left ventricular myocytes and isolated 
myocytes and multicellular ventricular preparations obtained from non-diseased human left ventricule, 
while RyR and cytochrome c levels were studied only in canine cells. Co-localization within pairs of 
the examined proteins was assessed by off-line image analysis using Pearson correlation coefficient. 
All values are presented as arithmetic means ± SEM. Statistical significance of differences was 
evaluated using one-way ANOVA followed by paired or unpaired Student's t-test as appropriate. 
Differences were considered significant when p was less than 0.05 and indicated with either asterisks 
or + symbols. 
 
 
3. Results 
 
3.1. Ca2+- and voltage-dependent behavior of ICl(Ca) assessed by conventional voltage-clamp 
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ICl(Ca) was defined as a 9-AC-sensitive current (I9-AC), i.e. as a difference current obtained by measuring 
the current before and after application of 0.5 mmol/L 9-AC during step depolarizations to a range of 
voltages from −60 to +60 mV. According to our earlier results, ICl(Ca) displayed a pronounced increase 
in its amplitude at membrane potentials positive to −40 mV when normal Ca2+ homeostasis was 
preserved (i.e. when the pipette solution was not buffered for Ca2+) [30]. ICl(Ca) activated rapidly, but 
declined to a value close to zero within 20 ms (Fig. 1A). To confirm its dependence on [Ca2+]i, the 
current was recorded in the presence of two chelators having different Ca2+ binding kinetics and 
affinity. Application of 10 mmol/L BAPTA in the pipette solution without the addition of Ca2+ 
resulted in a great reduction of ICl(Ca) making the current barely detectable at any test potential 
(0.07±0.01 A/F at +60 mV, Fig 1B). In contrast, application of 10 mmol/L EGTA in the pipette – 
although reduced ICl(Ca) amplitude significantly (from 2.44±0.28 A/F to 1.49±0.27 A/F at +60 mV) – 
but failed to eliminate the current. In addition, the voltage-dependence of ICl(Ca) in the presence and 
absence of EGTA was essentially similar (Fig 1B). 
The Ca2+-dependence of ICl(Ca) was further studied by application of a pipette solution designed to 
mimic the estimated peak systolic value of [Ca2+]i (1.1 µmol/L free Ca2+). This was achieved by 
adding BAPTA and appropriate amounts of Ca2+ to the pipette solution (see further details in the 
Supplement). The amplitude of ICl(Ca) was significantly larger when [Ca2+]i was set to 1.1 µmol/L 
(0.31±0.06 A/F at +60 mV in the 5 cells studied, not shown) comparing to values obtained with 
10 mmol/L BAPTA, however, it was much smaller than that measured without buffering [Ca2+]i. 
Applying 1 µmol/L nisoldipine, a selective inhibitor of L-type Ca2+ channels, further supported the 
Ca2+-dependent nature of ICl(Ca), since both L-type Ca2+ current (ICa,L) and ICl(Ca) were eliminated by 
nisoldipine (Fig. 1C). 9-AC had no influence on the amplitude of ICa,L in the 5 studied cells (Fig. 1D). 
These data are in line with the view that Ca2+-entry through L-type Ca2+ channels (in addition to the 
concomitant Ca2+-release from the SR) may be essential for the physiological activation of ICl(Ca). 
 
3.2. Influence of preserved Ca2+-homeostasis and buffered [Ca2+]i on ICl(Ca) recorded under APVC 
conditions 
 
The influence of [Ca2+]i buffering (by EGTA or BAPTA) as well as the preserved Ca2+-homeostasis 
(no calcium buffering) were further studied on AP configuration and on the simultaneously recorded 
calcium transients (CaTs). ICl(Ca) and ICa,L were studied using their specific blockers (9-AC and 
nisoldipine, respectively) during the AP applying sequential dissection of ionic currents under 
conditions of APVC. CaTs were completely abolished when 10 mmol/L of a Ca2+ buffer (BAPTA or 
EGTA) was added to the pipette solution, while characteristic CaTs could be observed without these 
buffers (Fig. 2A). Importantly, these CaTs recorded in whole-cell configuration without using Ca2+ 
buffers were not different from CaTs elicited with either field stimulation or by injecting current 
through sharp microelectrodes (data not shown). Under these conditions intracellular Ca2+-handling 
must be physiological in the absence of intracellular dialysis. In line with these results, unloaded cell 
shortening was equally abolished by either BAPTA or EGTA (not shown). 
Using BAPTA-containing pipette solution resulted in a massive prolongation of APs accompanied by 
a pronounced positive shift in the plateau potential. Phase-1 amplitude was decreased by both BAPTA 
and EGTA, this effect was greater in the case of BAPTA than EGTA. In contrast to BAPTA, EGTA 
failed to increase the duration of APs (Fig. 2B). Similarly, the profile of nisoldipine-sensitive current 
(INISO) was strongly different in the presence of the two Ca2+ buffers. BAPTA increased both the 
amplitude and integral of INISO significantly, while EGTA had no such effect on these parameters (Fig. 
2C). On the other hand, INISO displayed a pronounced early inactivation allowing a second inward peak 
to rise under Ca2+ buffer-free conditions in cells possessing a spike and dome type of AP. This second 
peak disappeared in the presence of the calcium buffers (Fig. 2C). 
9-AC dissected an early narrow outward current (Fig. 2D) having a peak value of 1.62±0.06 A/F 
which overlapped the phase-1 repolarization of the command AP (appearing 8.1±0.4 ms after the peak 
of the AP and 7.0±0.9 ms before the end of phase-1 repolarization) (Supplementary Fig. 1). The 
outward peak always appeared later than the inward peak of INISO by 6.4±0.5 ms when studied with 
Sequential Dissection on the same cells using 9-AC followed by nisoldipine (Supplementary Fig. 1). 
This outward peak of I9-AC was followed by a smaller late inward current reaching its maximum 
(−0.16±0.02 A/F) towards the end of the AP. BAPTA reduced significantly both the outward as well 
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as the inward components of I9-AC - the outward current peak decreased nearly to zero (See data in 
Supplementary Table 1). The effect of EGTA on the early outward current peak was smaller 
(1.17±0.09 A/F, p<0.05). These changes in current amplitudes were also reflected by similar 
alterations of current integrals (Fig. 2D). In summary, CaTs were completely eliminated by both Ca2+ 
buffers, while BAPTA but not EGTA abolished ICl(Ca) - probably due to a more effective buffering of 
[Ca2+]cleft. 
 
3.3. Effect of changes in [Cl−]i on the profile of ICl(Ca) measured with APVC 
 
In the APVC experiments described above, intracellular Cl− concentration ([Cl−]i) was set to 
47 mmol/L, yielding a Cl− reversal potential of −32 mV. In this case, without applying any Ca2+ 
buffer, I9-AC displayed initially an early outward component which was followed by a late inward 
component having peak densities of 1.62±0.08 A/F and −0.16±0.03 A/F, respectively, in the 15 cells 
studied (Fig. 3C and Supplementary Table 1). To test and reinforce the charge carrier, the 
concentration of Cl− in the pipette solution was lowered to 27 mmol/L (by replacing Cl− with 
equimolar aspartate) setting the new Cl− reversal potential to −47 mV. This reduction of [Cl−]i resulted 
in an enhancement of the amplitude and integral of the early outward component, while the late inward 
component was practically eliminated (Fig 3G, H and Supplementary Table 1). Plotting the phase-
plane trajectories of I9-AC revealed that regardless of the actual magnitude of [Cl−]i the outward current 
was the largest within a narrow voltage-range corresponding to phase-1 repolarization of the AP (Fig. 
3E, F). These data are considered as further supporting evidence that ICl(Ca) was indeed mediated by 
Cl−. 
 
3.4. Frequency-dependence of ICl(Ca) during physiological action potentials 
 
I9-AC profiles were tested at two different steady-state pacing rates under APVC conditions. As 
reported earlier [30], APD90 was increased by 9-AC in a reverse-rate dependent manner (Fig. 4A, B). 
According to the expectations, both systolic and diastolic [Ca2+]i were higher when the preparations 
were stimulated at 2 Hz than at 1 Hz (Fig. 4C). In line with the larger CaT, the density of I9-AC as well 
as the total charge carried by the outward component of the current significantly increased when 
stimulatory frequency was increased from 1 Hz to 2 Hz (Fig. 4D-F and Supplementary Table 1). 
 
3.5. ICl(Ca) is increased by enhancement of ICa,L 
 
As demonstrated by the experiments displayed in Fig. 1C and Fig. 2, ICa,L seems to play a critical role 
in the activation of ICl(Ca). In the next experiments ICa,L was enhanced by two different mechanisms. 
First a protein kinase A-dependent phosphorylation of the channel protein (Cav1.2) was induced by the 
β-adrenergic agonist isoproterenol (ISO) applied in a concentration of 10 nmol/L (Fig. 5) [31]. In 
another set of experiments direct pharmacological stimulation of ICa,L was achieved by 20 nmol/L of 
Bay K8644 (Fig. 5) [32]. As it was confirmed with the recording of CaTs, both interventions resulted 
in an increased systolic calcium concentration, although ISO was more potent in this regard (Fig. 5A, 
B). ISO acted similarly to Bay K8644: the plateau potential was increased and phase-1 amplitude was 
reduced by both interventions (Fig. 5C, D). In contrast, opposite effects were observed on the duration 
of the AP, since AP was shortened by ISO while lengthened by Bay K8644. This can be attributed to 
the enhancement of the slow delayed rectifier K+ current (IKs) by ISO [33]. IKs is not activated by Bay 
K8644 but ICa,L is expected to be increased by both 10 nmol/L ISO and 20 nmol/L Bay K8644. ICl(Ca) 
was dissected by 0.5 mmol/L 9-AC using the AP recorded in Tyrode solution as the command signal. 
Both inward and outward peaks of I9-AC were significantly larger after pretreatment with either 
10 nmol/L isoproterenol or 20 nmol/L Bay K8644 as compared to untreated controls (Fig. 5G). In 
addition, its profile, its amplitude and the total charge carried by I9-AC were similar after these 
pharmacological interventions, irrespective of the way of ICa,L enhancement (Fig. 5E-H). Enhancement 
of ICa,L led to a 2-fold increase in both the outward and the inward components of I9-AC (Supplementary 
Table 1). These results support the view that Ca2+-entry through the L-type calcium channels is 
critically important in the activation of ICl(Ca). 
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3.6. Blockade of SR Ca2+-release by ryanodine fails to abolish ICl(Ca) 
 
Contribution of CICR from the SR to the activation of ICl(Ca) was also examined. Superfusion of the 
cells with 10 µmol/L ryanodine for 15 min greatly reduced both CaT and cell shortening (Fig. 6A). 
Ryanodine exposure also resulted in the elevation of the early plateau phase of AP (Fig. 6B, C). 
However, 0.5 mmol/L 9-AC applied in the presence of ryanodine caused a further reduction of phase-1 
amplitude (Fig. 6B, C). Dissection of the corresponding ionic current by 9-AC under APVC 
conditions using the AP recorded in Tyrode solution as the command signal demonstrated a clear-cut 
ICl(Ca) in the presence of ryanodine, having its usual profile, although its amplitude was significantly 
smaller than that measured under control conditions (Fig. 6D, E, F, and Supplementary Table 1). 
Taken together, these data give strong support to our hypothesis stating that CICR is not essential for, 
but contributes to the activation of ICl(Ca) which is rather influenced by transsarcolemmal Ca2+ entry. 
 
3.7. Co-expression of TMEM16A, Bestrophin-3 and Cav1.2 in the t-tubules of canine left ventricular 
cells 
 
The expression pattern of potential channel protein candidates of ICl(Ca) has been studied using 
immunocytochemistry and confocal microscopy. Cav1.2, the pore forming subunit of ICa,L, was also 
assessed. The specificity of the applied antibodies was tested by omitting the primary antibodies 
during the incubation procedure and also by Western blotting and immunocytochemistry 
(Supplementary Fig. 2). According to expectations, Cav1.2 protein expression was most abundant in 
the t-tubules (Fig. 7A and Supplementary Fig. 3A). Importantly, strong co-localization was found 
between Cav1.2 and Bestrophin-3 indicated by the 0.74±0.03 value of the Pearson correlation 
coefficient (PCC) obtained in 8 cells prepared from 2 animals. TMEM16A showed a similar 
expression pattern and strong co-localization with Bestrophin-3 (Fig. 7B and Supplementary Fig. 3B) 
with a PCC of 0.74±0.06 (n=8/2). 
 
3.8. TMEM16A, Bestrophin-3, RyR and cytochrome c expression patterns in canine cardiomyocytes 
 
To exclude the possibility of an accidental co-expression and/or co-localization, the expression of 
channel protein candidates of ICl(Ca) was assessed together with other proteins. First the expression of 
cytochrome c was tested with TMEM16A (Supplementary Fig. 4A). In spite of the recognizable 
striated pattern of cytochrome c expression, the co-localization of cytochrome c and TMEM16A is 
unlikely as the merged image did not show strong overlap (PCC was 0.25±0.03 in 7 cells of 2 
animals). Although the co-localization of Bestrophin-3 with RyR was slightly stronger (PCC = 
0.36±0.05) in 3 cells of 3 animals (See supplementary Fig. 4B), it was much weaker than with Cav1.2. 
Similarly, the co-localization of TMEM16A with RyR was not pronounced (PCC of 0.31±0.01) in 3 
cells of 1 animal (not shown). 
 
3.9. Co-localization of TMEM16A, Bestrophin-3 and Cav1.2 in left ventricular tissues and isolated left 
ventricular cardiomyocytes obtained from non-diseased human hearts 
 
The expression pattern of TMEM16A and Bestrophin-3 has been studied using immunohistochemistry 
and confocal microscopy. Cav1.2 protein expression showed a striated pattern suggesting abundant 
expression in the t-tubules (Fig. 8A and Supplementary Fig. 5A). Similarly to the results obtained in 
isolated canine myocytes, strong co-localization was found between Cav1.2 and Bestrophin-3 indicated 
by the 0.71±0.02 value of PCC obtained in the 7 human cryosections studied. TMEM16A showed a 
similar expression pattern and strong co-localization with Bestrophin-3 (Supplementary Fig. 5B) with 
a PCC of 0.80±0.01, n=7). In case of isolated human cells even stronger co-localization was detected 
than in case of tissue samples or canine cells. PCC for Cav1.2 and Bestrophin-3 yielded a 0.84±0.02 
value obtained in 18 cells prepared from two non-diseased human hearts (Fig. 8A). TMEM16A 
showed a similar expression pattern and strong co-localization with Bestrophin-3 with a PCC of 
0.85±0.02 (n=5/2) (Fig. 8B). 
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4. Discussion 
 
4.1. Properties of ICl(Ca) 
 
The present study aimed to characterize ICl(Ca) in isolated canine ventricular myocytes under 
physiological conditions. This included the application of APVC allowing to record the current during 
the physiological AP waveform [34] and using pipette solution without buffering of [Ca2+]i allowing to 
develop CaTs with normal kinetics. This is critically important in the case of a Ca2+-sensitive current, 
like ICl(Ca). 
Although several studies described ICl(Ca) in various cardiac preparations [11, 12, 19, 23, 24, 35], the 
properties of ICl(Ca) under true APVC conditions (i.e. when the current is studied during an AP recorded 
from the same myocyte) have not been analyzed. Furthermore, nonspecific blockers of the current, like 
4-acetamido-4'-isothiocyanostilbene-2,2'-disulfonic acid (SITS) and 4,4’-diisothiocyanostilbene-2,2’-
disulfonic acid (DIDS) were applied for dissection of ICl(Ca) in the majority of these studies, which 
compounds are known to block Na+ current as well [30]. In the only work performed to study canine 
cardiac ICl(Ca) using APVC combined with perforated patch clamp technique a “typical” AP was 
applied as the command signal and nonspecific blockers were used to dissect ICl(Ca) [36]. 
Selectivity of the applied inhibitor, 9-AC is of major importance in this study. It is critical not to alter 
ICa,L when a Ca2+-dependent current such as ICl(Ca) is investigated. Fig. 1D indicates that 0.5 mmol/L 
9-AC has no influence on the amplitude of ICa,L. The major K+ currents, including IKr, IKs and IK1 were 
also unaltered by the same dose of 9-AC as we have shown previously [30]. It must be noted, 
however, that 9-AC was shown to also inhibit Cl− channels other than the Ca2+-activated ones. Volume 
regulated Cl− current was unlikely to be involved in our experiments because the osmolarity of the 
perfusion fluid was carefully adjusted. 9-AC was shown to reduce ISO-induced cAMP-dependent Cl− 
current as well in guinea pig ventricular myocytes [37], but these channels are not expressed in canine 
[38] and human hearts [39]. 
ICl(Ca) was reported to be a rapidly activating and outwardly rectifying transient current having a bell-
shaped I-V relation in the range of −40 and +100 mV when studied using rectangular voltage pulses 
[12]. Our data show that ICl(Ca), defined as 9-AC-sensitive current, possesses several properties similar 
to those reported previously under conventional voltage-clamp conditions. (1) ICl(Ca) began to activate 
at −20 mV, its amplitude grew with increasing depolarizations having the largest peak around +60 
mV, and declined at more positive voltages (not shown, but see Váczi et al. [30]). (2) Time-dependent 
decay of ICl(Ca) during these depolarizing pulses, similarly to its activation, was rapid. (3) Activation of 
ICl(Ca) required Ca2+ since it was abolished in the presence of nisoldipine or 10 mmol/L BAPTA (Fig. 
1). (4) Changes of current amplitude with partial replacement of Cl− by non-permeant anion in the 
pipette were deducible from the concomitant shift in the Cl− reversal potential. These similarities were 
evident in spite of the different experimental conditions. 
The profile of ICl(Ca), when studied as a 9-AC-sensitive current (I9-AC) using APVC, was composed of a 
fast, early outward and a late inward component. The outward component showed a rapid activation as 
well as a remarkable rapid decay in spite of the continuously elevated [Ca2+]i and the existing large 
driving force for Cl− influx. One possible explanation for this rapid decay of ICl(Ca) might be the time 
dependent inactivation of the channels mediating ICl(Ca). It had been shown, however, that in the case 
of a constant [Ca2+]i ICl(Ca) showed a time-independent behavior upon prolonged depolarization [12] 
making this option questionable. The same study also suggested the existence of a low-affinity Ca2+ 
binding site evoking inactivation of ICl(Ca) [12]. The possible mechanism for Ca2+-dependent 
inactivation (CDI) was studied in TMEM16A channels expressed in HEK cells, where 
phosphorylation by a Ca2+-calmodulin dependent protein kinase II was suggested [40]. This however 
is unlikely to mediate CDI during the AP. A more likely explanation for the rapid decay of ICl(Ca) may 
be the rapid and massive reduction of [Ca2+]cleft, a change much faster and grater than observed with 
[Ca2+]i [41, 42]. This is in line with the co-localized arrangement of the Ca2+ and Cl− channels 
allowing a direct guidance of ICl(Ca) by [Ca2+]cleft, which is strictly controlled by the neighboring Ca2+ 
channels. Moreover, it was shown that calmodulin can inactivate TMEM16A at [Ca2+] higher than 10 
µmol/L at least in HEK cells [43]. 
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The late inward component in the profile of ICl(Ca) appearing towards the end of the AP also needs 
discussion. According to our hypothesis the current is activated due to the combination of membrane 
potential and an appropriate value of [Ca2+]cleft which it is still able to activate ICl(Ca) but not too high to 
cause calmodulin dependent inactivation [43]. During terminal repolarization the membrane potential 
reduces below the equilibrium potential of Cl− (−32 mV in our experiments except when low [Cl−]i 
was used) therefore an inward current is generated through open channels by the efflux of Cl−. 
The source of the increase of [Ca2+]cleft during diastole can be the spontaneous Ca2+-release through 
ryanodine receptors in a Ca2+-overloaded cell [44, 45]. The increase of [Ca2+]cleft can result in 
formation of arrhythmogenic delayed afterdepolarizations (DAD) by forward mode operation of NCX 
and ICl(Ca) activation [26]. Activation of ICl(Ca) in canine ventricular cells [12] as well as in ovine 
Purkinje cells and ventricular myocytes [46] was responsible for DAD formation highlighting the 
pathophysiological significance of ICl(Ca). 
However, in a cell without Ca2+-overload increase of [Ca2+]cleft to a level where it can activate ICl(Ca) at 
the end of the AP is difficult to explain. One option is the amplification of the window current of Ca2+ 
channels [47, 48] towards the end of the AP due to the growing driving force for Ca2+-influx. ICa,L 
mediated Ca2+-influx due to the reactivation of L-type Ca2+ channels during terminal repolarization 
was observed in guinea-pig ventricular myocytes [49]. In some canine ventricular cells a similar late 
inward peak of INISO measured in normal Ca2+ homeostasis (lack of exogenous Ca2+-buffering) was 
also present (own unpublished observation). 
Another option is the release of Ca2+ from myofilaments at the end of the AP [50] which is extruded 
via NCX and might also lead to the activation of ICl(Ca). Experimental evidence exists showing this late 
activation of forward mode NCX at the end of the AP in guinea-pig ventricular cells [49] and also in 
canine cells [34]. Indeed, we have observed similar timing of this inward INCX component and the final 
inward ICl(Ca) recorded in the same cell (own unpublished observation). 
Moreover, late Na+ current is largest towards the late plateau of the AP measured in APVC during 
intact Ca2+ homeostasis [45]. This Na+-influx slows down the previously mentioned Ca2+-extrusion via 
forward mode NCX therefore delays the reduction of [Ca2+]cleft which might also contribute to the 
activation of ICl(Ca). 
Finally, the late inward component of ICl(Ca) could be due to the reopening of Cl− channels at the end of 
the AP. During the majority of the plateau phase of the AP TMEM16A can be inactive because high 
[Ca2+] inactivates TMEM16A via calmodulin [43]. Upon the reduction of [Ca2+]cleft Ca2+ can gradually 
dissociate from the low affinity binding site of calmodulin leading to the suspension of CDI of 
TMEM16A channels. In this scenario [Ca2+]cleft can be large enough to activate ICl(Ca) but lower than 
that which causes calmodulin mediated CDI. 
 
4.2. Ca2+-entry via ICa,L is essential for the activation of ICl(Ca), while Ca2+-release from SR only 
augments ICl(Ca) 
 
Previous studies emphasized the principal role of SR Ca2+-release in the activation of ICl(Ca) in rabbit 
atrial myocytes and Purkinje fibers [18, 19]. In these studies long lasting (30-60 min) perfusion with 
ryanodine strongly reduced the amplitude of CaTs eliminating contractions and ICl(Ca). In contrast, we 
always observed large amplitude of ICl(Ca) in canine myocytes in the continuous perfusion of 
10 µmol/L ryanodine started 15 min prior to recording (Fig. 6). One might argue that 15 min 
pretreatment is not enough to achieve the blockade of Ca2+-release from SR but this is unlikely since 
both CaTs and cell shortening were largely abolished within 8-10 min of ryanodine perfusion (Fig. 
6A). Further possible reason for the observed differences in ryanodine-sensitivity of ICl(Ca) might be the 
different animal model used or other differences in experimental conditions. We applied canine 
ventricular cells in the present study in contrast to others using atrial myocytes and Purkinje fibers of 
the rabbit [18, 19], although in a third study elimination of ICl(Ca) by ryanodine was reported in 
conventional voltage-clamp experiments conducted in canine ventricular cells [12]. It is important to 
note that 9-AC was capable of decreasing phase-1 amplitude even in the presence of ryanodine (Fig. 
6B, C). Furthermore, the profile of ICl(Ca) recorded under APVC conditions in the presence of 
ryanodine (Fig. 6D) was very similar to that seen without ryanodine (Fig. 3C) further confirming that 
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in our experimental setting Ca2+-release from the SR is not an absolute requirement for the activation 
of ICl(Ca). 
In contrast to the limited efficacy of ryanodine to eliminate ICl(Ca) in our measurements, blockade of 
Ca2+-entry through LTCCs by nisoldipine fully abolished ICl(Ca). Previous studies using calcium 
channel blockers, like cadmium, nisoldipine, and nicardipine described similar results [11, 51]. INISO 
peak always occurred earlier than the peak of ICl(Ca) in our experiments (Supplementary Fig. 1.) further 
confirming the essential role of Ca2+-entry through LTCCs in the physiological activation of ICl(Ca). It 
must be mentioned, however, that INISO is not exclusively composed of ICa,L but it also contains all the 
electrogenic processes which are influenced by Ca2+. The reason for it is that although nisoldipine 
itself is highly selective for LTCC [34] but it also eliminates the major route of Ca2+-entry to the cell. 
As a consequence, the trigger for CICR is reduced leading to a drop in both [Ca2+]cleft and [Ca2+]i. 
Among those Ca2+-dependent processes which could be part of INISO one can find the current mediated 
by Na+/Ca2+ exchange (INCX), Ca2+-dependent K+ channels, TRP channels and ICl(Ca) itself. The 
contribution of ICl(Ca) is not an issue in our experiments because nisoldipine was applied in the 
presence of 9-AC therefore ICl(Ca) has already been eliminated. Ca2+-dependent K+ channels and TRP 
channels are unlikely to make a large contribution [52] to INISO which leaves INCX as the other main 
component of INISO. INCX can be an outward current leading to Ca2+-influx at the beginning of the 
cardiac AP but this is limited to a few milliseconds [49, 53]. Na+/Ca2+ exchanger generates mainly an 
inward current during the cardiac AP [49, 54] which contributes to a smaller or larger extent to INISO. 
According to Janvier et al. the two currents (INCX and ICa,L) have equal contribution to the inward 
current during the plateau phase of ferret ventricular AP [54]. However, according to results obtained 
using guinea pig ventricular cells under experimental conditions similar to our current study, the 
contribution of INCX to INISO is much smaller especially during the early phase of AP plateau (only 
about 25-30%) [49]. During the late plateau the contribution of INCX and ICa,L to INISO becomes roughly 
equal [54]. In our experiments we observed a substantial prolongation of the AP in the presence of 
10 mmol/L BAPTA applied in the pipette solution (Fig. 2B), similarly to what has been described in 
our earlier study also on canine cells in the presence of 5 µmol/L BAPTA-AM [55]. This is in great 
contrast with the study of Janvier et al. where the AP became shorter after the application of 5 µmol/L 
BAPTA-AM [54]. This shortening was explained by the reduction of INCX and therefore the smaller 
overall depolarizing drive during the plateau phase in the presence of BAPTA-AM. The enhancement 
of ICa,L due to the lack of CDI of LTCC by strong [Ca2+]cleft buffering can lead to the prolongation of 
the AP as seen in this study (Fig. 2). This phenomenon, however, was not emphasized in the study of 
Janvier et al. On the contrary, buffering Ca2+ increased ICa,L about eight times compared to the 
physiological conditions according to modeling results in the guinea pig cells [49]. It seems therefore 
that the main effect of Ca2+-buffering in canine and guinea-pig cells is the enhancement of ICa,L 
whereas in ferret ventricular cells the reduction of INCX dominates explaining the opposite actions of 
Ca2+-buffering on the duration of the AP. Our results therefore suggest that INCX is less dominant in the 
dog than in ferret but it is more similar to that of guinea pig in the maintenance of AP plateau. Another 
option is that in case of canine cells the dominant effect of Ca2+-buffering is the increase of ICa,L 
resulting in AP prolongation. 
Our other experiments support the importance of Ca2+-entry through LTCCs further. The amplitude of 
ICl(Ca) strongly increased when ICa,L was enhanced either by ISO or Bay K8644 (Fig. 5). Both drugs 
increases ICa,L but as Bay K8644 does not phosphorylate channel proteins (unlike what is the case in 
the presence of ISO), direct interaction with the Ca2+-activated Cl− channels can be excluded in this 
case. However, both treatments increased ICa,L (not shown) and ICl(Ca) amplitudes to the same extent, 
while the concomitant elevations of CaT amplitudes were not proportional (Fig. 5). In line with this 
view, increasing the stimulation rate from 1 to 2 Hz also increased ICl(Ca) probably due to the increased 
transsarcolemmal Ca2+ entry (Fig. 4). 
Co-localization studies have revealed that LTCCs and RyRs are in close proximity to one another 
within the dyadic cleft [56]. During excitation-contraction coupling [Ca2+]cleft is believed to be much 
higher and has faster kinetics than in the bulk cytoplasm [41, 42]. However, measuring [Ca2+]cleft 
directly is just becoming available [42, 57]. According to our hypothesis, ICl(Ca) is controlled locally, 
by [Ca2+]cleft, rather than bulk [Ca2+]i. This approach is supported by the experiments aiming to set 
[Ca2+]i to 1.1 µmol/L (which corresponds to peak value of systolic [Ca2+]i) by dialyzing cells with 
pipette solution containing 1.1 µmol/L of free Ca2+. In this case, ICl(Ca) amplitude was much smaller, 
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only 13 % of the value obtained without buffering [Ca2+]i. This is in a good agreement with the Ca2+-
sensitivity of ICl(Ca) determined in murine airway smooth muscle, where the EC50 was estimated to be 
3.3 µmol/L but only 20-50 µmol/L [Ca2+]i resulted in full activation of the current [58]. Therefore, the 
significantly larger ICl(Ca) measured under physiological conditions, i.e. without buffering [Ca2+]i, is 
probably due to the higher [Ca2+]cleft. 
The different actions of EGTA and BAPTA on ICl(Ca) and ICa,L can also be explained by the ability of 
Ca2+ chelators to differentially affect [Ca2+]i and [Ca2+]cleft [59]. These agents suppress ICl(Ca) and CDI 
of ICa,L with different efficacy. Although both buffers eliminated CaTs (Fig. 2A), only BAPTA was 
effective to suppress CDI of ICa,L resulting in significantly higher INISO amplitude and total charge 
values (Fig. 2C) in addition to the much longer AP (Fig. 2B). BAPTA fully eliminated ICl(Ca) during 
the AP, while EGTA only decreased its amplitude and the total charge carried by the current (Fig. 2D). 
These results are in a good agreement with the conventional voltage-clamp observations (Fig. 1B). 
The reason for the different buffering efficacy is that BAPTA has a 100 times faster binding rate to 
Ca2+ than EGTA [59]. Similarly to the present study, effects of the two buffers were compared on 
large-conductance Ca2+-activated K+ channels (BKCa) [60]. In line with our findings, namely that 
[Ca2+]cleft could be buffered by the rapidly acting BAPTA, but not by EGTA, BKCa channels could be 
activated by Ca2+ in the presence of EGTA, while the current was fully abolished by BAPTA [60]. 
As mentioned previously, blockade of Ca2+-release from the SR failed to fully abolish ICl(Ca), only 
some reduction of the current amplitude was observed. It is rather difficult, however, to judge the 
relative contribution of Ca2+-entry through LTCC and Ca2+-release from SR to the activation of ICl(Ca). 
One reason is that the CDI of ICa,L is known to be reduced when Ca2+-release from SR is blocked (e.g. 
in the presence of ryanodine). Therefore the relative contribution of LTCCs to ICl(Ca) activation is 
probably overestimated in the presence of ryanodine. Determining the precise contribution of these 
two mechanisms is further complicated by the presence of several other Ca2+-dependent processes 
involved in the ventricular electrical activity, including the Na+/Ca2+ exchanger, Ca2+-dependent K+ 
channels, and various Ca2+ pumps, likely to be altered by changes in [Ca2+]i and even more by 
alterations in [Ca2+]cleft. It would be important, therefore, to measure the [Ca2+]cleft directly in the 
vicinity of the LTCC and Ca2+-activated Cl− channels. It must be mentioned however that in this study 
we only examined the source of Ca2+ that activates ICl(Ca) (via Ca2+-entry from the extracellular space 
or Ca2+ released from the SR) but we did not discriminate the route of Ca2+-entry (via LTCC or reverse 
mode NCX). The contribution of Ca2+-entry via NCX is unlikely to play a major role if any in 
activating ICl(Ca) (note the lack of outward current on INISO trace on the cell shown on Supplementary 
Fig. 1) but can not be excluded. 
 
4.3. Co-localization of Cav1.2 with TMEM16A and Bestrophin-3 proteins, possible contributors of 
ICl(Ca) 
 
In this study we tested the co-localization of Bestrophin-3 and/or TMEM16A, the two likely 
candidates responsible for ICl(Ca) [13-16], with Cav1.2 protein. The expression of Bestrophin-1 was 
demonstrated in murine heart. Moreover, when Bestrophin-1 was extracted and transfected to HEK 
cells, the resultant current recapitulated the characteristics of ICl(Ca), including Ca2+-dependence, anion 
selectivity and sensitivity to DIDS or niflumic acid [61]. The same group reported the expression of 
Bestrophin-3 in murine and human heart (although only at mRNA level in the latter) similarly to 
Bestrophin-1 [62]. Bestrophin-3, when expressed in HEK cells, was activated by Ca2+ with the Kd of 
175 nmol/L, and blocked by micromolar concentrations of DIDS and niflumic acid [62]. The cellular 
expression of Bestrophin-3 in murine ventricular cells showed a punctuated pattern which was strong 
in the sarcolemma [62]. In our images obtained in canine ventricular myocytes the cellular expression 
of Bestrophin-3 showed striated pattern rather than being punctuated. Bestrophin-3 expression in 
human samples (left ventricular myocardium as well as isolated left ventricular cells), similarly to that 
seen in canine cells, showed striated pattern. 
Cardiac expression of TMEM16A has been described in murine ventricle [17], but this is the first 
report demonstrating it in canine and human ventricular preparations. In both species a clear-cut 
striated pattern was observed. Importantly, the expression of Bestrophin-3 showed strong co-
localization with Cav1.2 channel protein (Fig. 7A and 8A) and TMEM16A (Fig. 7B and 8B) making it 
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very likely that Cav1.2 and TMEM16A also co-localize with one another. In line with the results of the 
present study Ca2+-activated Cl− channels localize close to RyR and are controlled by local Ca2+ 
signals in airway smooth muscle [58]. On the contrary to our finding in rat dorsal root sensory neurons 
TMEM16A channels were reported to be activated by G protein-coupled receptor induced Ca2+ 
release, but not by Ca2+-influx through voltage-gated Ca2+ channels [21]. As a mechanism behind this 
the tethering of TMEM16A- and G protein-coupled receptor-containing, caveolin-1 enriched plasma 
membrane domains to juxtamembrane regions of the endoplasmic reticulum was mentioned. Here 
inositol 1,4,5-trisphosphate receptor 1 is the interacting partner of the carboxyl terminus and first 
intracellular loop of TMEM16A while voltage-gated Ca2+ channels are located in other parts of the 
plasma membrane [21]. On cardiac muscle however caveolin-3 is associated to the same compartment 
with Cav1.2 proteins among many other [63]. Moreover, in case of hippocampal neurons TMEM16B 
was reported to appear in close proximity of Ca2+ channels and NMDA receptors [64]. 
In addition, Bestrophins can associate with TMEM16A and contribute to the functional channel in 
vascular smooth muscle cells [65]. This possibility, however, is very difficult to test since TMEM16A 
modulates Bestrophin expression [66]. Down-regulation of TMEM16A reduced the expression of 
Bestrophins, however, a reduced expression of LTCCs has also been mentioned [66]. On the other 
hand, Bestrophins were shown to form preferentially homomeric channels [67], similarly to 
TMEM16A [68], which may question the ability of the two proteins to form a single functional ion 
channel. 
The striated pattern of TMEM16A, Bestrophin-3, and Cav1.2 expression is most likely due to the 
strong expression of these proteins in the membranes of the t-tubules (Fig. 7 and 8). Similar images 
were published in murine and human ventricular cardiomyocytes with Cav1.2 expression in the t-
tubules [69]. The accidental co-localization of the channel proteins due to technical factors of imaging 
is unlikely since the co-localization of TMEM16A with cytochrome c was weak (Supplementary Fig. 
4A). Similarly, less pronounced co-localization was seen between Bestrophin-3 and RyR 
(Supplementary Fig. 4B) than between Bestrophin-3 and TMEM16A/Cav1.2 (Fig. 7 and 8). The 
expression pattern of RyR was very similar to that seen in rat ventricular myocytes [70]. The co-
localization of Cav1.2 with RyR and RyR with Cav1.2 was approximately 57 and 37 %, respectively, 
in adult rat ventricular myocytes [55]. 
 
4.4. Summary 
 
The major finding of the present study was to show that Ca2+-entry through LTCC is sufficient for the 
activation of ICl(Ca) and does not require Ca2+-release from the SR through RyR. Our results 
demonstrate the expression of Bestrophin-3 and TMEM16A in both canine and human ventricular 
preparations for the first time and the strong co-localization of Bestrophin-3 with TMEM16A and 
Cav1.2 protein. Elucidation of the exact roles of TMEM16A and/or Bestrophin-3 in the formation of 
ICl(Ca), however, requires further studies.  
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Fig. 1.  Ca2+- and voltage-dependence of ICl(Ca) in canine ventricular myocytes. 
(A) Representative ICl(Ca) traces, determined as 0.5 mmol/L 9-AC-sensitive current (I9-AC), at test 
potentials ranging from −60 to +60 mV without applying a Ca2+ buffer in the pipette (voltage protocol 
shown in the inset). (B) I9-AC amplitudes plotted as a function of the test potential under various 
intracellular Ca2+-buffering conditions: without Ca2+ buffer, 10 mmol/L EGTA or 10 mmol/L BAPTA 
in the pipette solution). (C) Voltage-dependence of I9-AC and ICa,L measured without Ca2+ buffer in 
control (in Tyrode) and in the presence of 1 µmol/L nisoldipine (in NISO). (D) ICa,L amplitude 
measured in the absence (open diamonds) and presence of 0.5 mmol/L 9-AC (filled circles). Symbols, 
columns and bars represent mean ± SEM values. Asterisks denote significant difference from control, 
n indicates the number of experiments (number of cells / number of hearts). 
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Fig. 2.  Effect of various intracellular buffering conditions on the simultaneously recorded cardiac AP, 
intracellular Ca2+ transient (CaT), INISO, and I9-AC. 
Cells were voltage-clamped through pipettes containing no Ca2+ buffer (n=4/2, where number of cells / 
number of hearts is given), 10 mmol/L EGTA (n=9/4) or 10 mmol/L BAPTA (n=6/3). (A) 
Representative CaTs (average of ten traces, measured with Fura-2-AM), diastolic [Ca2+]i, and CaT 
amplitude. (B) Superimposed representative APs, phase-1 amplitudes, and action potential duration 
(APD90). (C) Representative INISO traces (1 µmol/L nisoldipine-sensitive current), INISO peak and total 
charge. (D) APVC recordings of ICl(Ca) (0.5 mmol/L 9-AC-sensitive current), I9-AC peak densities and 
total charges carried by outward (white columns) and inward currents (black columns). The first 35 ms 
of the representative traces is displayed enlarged in the inset. Columns and bars indicate mean ± SEM 
values, asterisks denote significant differences from unbuffered condition, + symbols indicate 
significant differences between the effects of EGTA and BAPTA. 
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Fig. 3.  Influence of [Cl−]i on ICl(Ca) profile during self AP voltage-clamp recordings. 
The pipette solution contained either 47 mmol/L (A, C, E) or 27 mmol/L Cl− (B, D, F). Representative 
APs (A, B) and the corresponding APVC recordings of I9-AC (C, D) are displayed. Panels E and F 
show phase-plane trajectories generated by plotting I9-AC amplitudes against the corresponding values 
of membrane potential. Arrows indicate the temporal sequence. I9-AC peak densities (G) and total 
charges (H) estimated for outward (white columns) and inward currents (black columns). Columns and 
bars indicate mean ± SEM values, asterisks denote significant differences from data obtained with 
47 mmol/L Cl− containing pipettes. n indicates the number of experiments where number of cells / 
number of hearts is given. 
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Fig. 4.  Rate-dependence of ICl(Ca) under APVC conditions. 
Upper panels show representative APs in control and in 0.5 mmol/L 9-AC at 1 (A) and 2 Hz (B) 
stimulatory frequencies. Representative Ca2+ transients (C) and I9-AC traces (D) recorded at these 
pacing rates. I9-AC peak densities (E) and total charges (F) measured during outward (white columns) 
and inward currents (black columns). The first 30 ms of the current traces is shown enlarged in the 
inset of panel D. Columns and bars indicate mean ± SEM values, asterisks denote significant 
differences from data obtained at 1 Hz. Number of experiments at both frequencies were 5 cells / 3 
hearts. 
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Fig. 5.  Stimulation of ICl(Ca) by isoproterenol and Bay K8644. 
Representative traces of Ca2+ transients (A, B) and APs (C, D) in control and in the presence of either 
10 nmol/L isoproterenol (ISO, A and C) or 20 nmol/L Bay K8644 (B and D). Representative ICl(Ca) 
records, dissected by 0.5 mmol/L 9-AC using the AP recorded in Tyrode solution as the command 
signal, in the presence of ISO (E) and Bay K8644 (F). I9-AC peak densities (G) and total charges (H) 
estimated for outward (white columns) and inward currents (black columns). Columns and bars 
indicate mean ± SEM values, asterisks denote significant differences from control. n indicates the 
number of experiments where number of cells / number of hearts is given. 
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Fig. 6.  Role of SR Ca2+-release in ICl(Ca) activation. 
(A) Effects of ryanodine on Ca2+ transient (top) and cell shortening (bottom) in a field-stimulated 
myocyte. (B) Representative traces of APs recorded in Tyrode solution (control), in the presence of 
10 µmol/L ryanodine and following an additional superfusion with 0.5 mmol/L 9-AC. (C) Average 
phase-1 amplitudes and APD90 values obtained under the above conditions in 4 myocytes of 3 animals. 
(D) Representative ICl(Ca) record measured in the presence of ryanodine with APVC. ICl(Ca) was 
dissected by 0.5 mmol/L 9-AC (I9-AC) using the AP recorded in Tyrode solution as the command 
signal. E and F panels show average results on I9-AC peak densities and total charges flowing during 
the outward (white columns) and inward (black columns) current components. Columns and bars 
indicate mean ± SEM values, asterisks denote significant differences from control. n indicates the 
number of experiments where number of cells / number of hearts is given. 
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Cav1.2 (red) + Bestrophin-3 (green) + nuclei (blue) + Merged
A
B
TMEM16A (red) + Bestrophin-3 (green) + nuclei (blue) + Merged
 
Fig. 7.  Confocal images showing the expression pattern of Cav1.2, TMEM16A, and Bestrophin-3 in 
canine ventricular myocytes. 
(A) Representative cell showing the expression of Cav1.2, Bestrophin-3, and nuclear staining in red, 
green, and blue, respectively, from left to right. The far right panel represents the overlay of the three 
images. 
(B) Representative cell showing the expression of TMEM16A, Bestrophin-3, and nuclear staining in 
red, green, and blue, respectively, from left to right. The far right panel represents the overlay of the 
three images. 
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Cav1.2 (red) + Bestrophin-3 (green) + nuclei (blue) + Merged
A
B
TMEM16A (red) + Bestrophin-3 (green) + nuclei (blue) + Merged
 
 
Fig. 8.  Confocal images showing the expression pattern of Cav1.2, TMEM16A, and Bestrophin-3 in 
left ventricular myocytes obtained from non-diseased human hearts. 
(A) Representative cell showing the expression of Cav1.2, Bestrophin-3, and nuclear staining in red, 
green, and blue, respectively, from left to right. The far right panel represents the overlay of the three 
images. 
(B) Representative cell showing the expression of TMEM16A, Bestrophin-3, and nuclear staining in 
red, green, and blue, respectively, from left to right. The far right panel represents the overlay of the 
three images. 
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Detailed Methods 
All reagents were dissolved in DMSO or 96 % ethanol. Equivalent volumes of solvents did not affect 
any of the physiological parameters studied. The osmolarity of all extracellular solutions were 
carefully adjusted to 295 ± 3 mmol/kg with a vapor pressure osmometer (Vapro 5520, Wescor Inc., 
Logan, UT, USA). 
 
Isolation of canine left ventricular myocytes 
Cell isolation was carried out by enzymatic dispersion using the segment perfusion technique 
described previously [1]. Adult healthy beagle dogs of both sexes were anesthetized by intramuscular 
application of a mixture of 10 mg/kg ketamine hydrochloride (Calypsol, Richter Gedeon, Budapest, 
Hungary) and 1 mg/kg xylazine hydrochloride (Sedaxylan, Eurovet Animal Health BV, Bladel, The 
Netherlands). After achieving complete narcosis, the chest was opened, the heart was quickly removed 
and washed in cold Tyrode solution containing (in mmol/L): NaCl 144, KCl 5.6, CaCl2 2.5, 
MgCl2 1.2, 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) 5, glucose 10 (pH = 7.4; 
adjusted with NaOH). The left anterior descending coronary artery was cannulated and perfused with a 
nominally Ca2+-free JMM solution (Minimum Essential Medium Eagle, Joklik Modification, product 
no. M0518) supplemented with the followings: 2.5 g/L taurine, 200 mg/L NaH2PO4, 1.4 g/L NaHCO3, 
175 mg/L pyruvic acid, 13.5 mg/L allopurinol, and 750 mg/L D-ribose, having pH of 6.8. JMM 
solution was gassed with a mixture of 95 % O2 and 5 % CO2. Then a wedge-shaped section of the left 
ventricular wall supplied by the left anterior descending coronary artery was dissected. Following 
further 5 min of perfusion to completely remove blood from the tissue, 0.9 g/L collagenase (type II, 
245 U/mg; Worthington Biochemical Co., Lakewood, NJ, USA), 2 g/L bovine serum albumin 
(Fraction V.), and 50 µmol/L CaCl2 were added to the JMM solution. Enzymatic digestion took 
usually 25-35 minutes which was followed by the collection of isolated cells. During the enzymatic 
digestion the solution was kept at 37 ºC. The tissue was cut with a scalpel and the middle portion of 
the free left ventricular wall containing mainly midmyocardial cells was cut into pieces, sedimented 
and filtered four times to remove big chunks. During this procedure Ca2+ concentration of the JMM 
solution was gradually restored to the final value of 1.8 mmol/L. Finally, cells were placed into MEM 
solution (Minimum Essential Medium Eagle, product no. M0643) supplemented with the followings: 
2.5 g/L taurine, 200 mg/L NaH2PO4, 2.2 g/L NaHCO3, 175 mg/L pyruvic acid, 13.5 mg/L allopurinol, 
750 mg/L D-ribose (pH = 7.3, achieved by bubbling the solution with a mixture of 95 % O2 and 
5 % CO2) and stored at 15 ºC until use. The percentage of living cells, showing clear cytoplasm and 
striations with sharp edges, was typically 30-60 %. 
 
Isolation of left ventricular myocytes from non-diseased human donor hearts 
Cell isolation was carried out by enzymatic dispersion as described previously [2]. 
 
Electrophysiology 
Cells were placed in a 1 mL volume plexiglass chamber and continuously superfused with Tyrode 
solution supplied by a gravity driven system at a speed of 2 mL/min. During experiments the bath 
temperature was set to 37 ºC by a temperature controller (Cell MicroControls, Norfolk, VA, USA). 
The cells were visualized by an inverted microscope (Eclipse TE2000-U, Nikon, Japan) placed in a 
Faraday cage on an anti-vibration table. Electrical signals were recorded with intracellular amplifiers 
(MultiClamp 700A or 700B, Molecular Devices, Sunnyvale, CA, USA) and recorded with pClamp 10 
software (Molecular Devices) after analogue-digital conversion (Digidata 1440A or 1332, Molecular 
Devices). Electrodes were fabricated from borosilicate glass having tip resistances of 2-3 MΩ after 
filling with pipette solution. Membrane currents were recorded using the whole-cell configuration of 
the patch-clamp technique. After establishing high (1-10 GΩ) resistance seal by gentle suction, the cell 
membrane beneath the tip of the electrode was disrupted by further suction or by applying 1.5 V 
electrical pulses for 1 ms. The series resistance was typically 4-6 MΩ. Experiments were discarded 
when the series resistance was high or substantially increased during the measurement. To preserve the 
normal Ca2+ homeostasis, we used internal solution containing (in mmol/L): K-aspartate 110, KCl 45, 
K2-ATP 3, MgCl2 1, HEPES 5, pH = 7.2 (adjusted using KOH). To examine the influence of the Cl− 
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concentration on ICl(Ca), 20 mmol/L of KCl was replaced by the same amount of K-Aspartate. In 
experiments aimed to eliminate [Ca2+]i transients during the AP, 10 mmol/L EGTA or 10 mmol/L 
BAPTA were used in the pipette (without adding any Ca2+), and the concentration of K-Aspartate was 
compensatory reduced in both cases. To buffer intracellular free Ca2+ to 1.1 µmol/L [3] we used the 
internal solution containing (in mmol/L): K-Aspartate 107, KCl 38, K2-ATP 3, MgCl2 1, HEPES 5, 
BAPTA 4.5, CaCl2 3.5 (pH = 7.2). In case of ICa,L measurement, 3 mmol/L 4-aminopyridine was 
added to the Tyrode solution and the internal solution contained (in mmol/L) KCl 110, KOH 40, 
HEPES 10, EGTA 10, tetraethylammonium chloride 20, K2-ATP 3 (pH = 7.2 with KOH). The 
osmolarity of all internal solutions was between 284 and 288 mmol/kg. 
ICl(Ca) was defined as a 9-AC-sensitive current (I9-AC) obtained by pharmacological subtraction [1]. In 
conventional voltage-clamp measurements, ICl(Ca) was determined within the voltage range of −60 to 
+60 mV using 200 ms long voltage pulses arising from the holding potential of −40 mV and applied at 
a rate of 0.2 Hz. Current–voltage relations for ICa,L were obtained by applying a series of 400-ms-long 
test pulses at 0.2 Hz increasing up to +60 mV in 10 mV steps from the holding potential of −40 mV. 
Current amplitudes were calculated as differences between peak and pedestal values. 
During APVC experiments Sequential Dissection experiments were conducted according to the 
method described previously [4, 5]. Action potentials were recorded in whole-cell configuration of 
current-clamp mode from the myocytes superfused with Tyrode solution. The pipette solution was 
identical to that used for the normal Ca2+ homeostasis condition (see above). Cells were continuously 
paced through the patch-pipette with supra-threshold depolarizing pulses of 1-2 ms duration delivered 
at steady stimulation frequency of 1 Hz (except when 2 Hz stimulation was used on Fig. 4.) so as a 1-
2 ms gap between the stimulus artifact and the upstroke of the AP could occur. Ten subsequent APs 
were recorded and immediately analyzed from each cell. One of these APs, recorded always in pure 
Tyrode solution, having duration (and overall shape) closest to the average, was delivered to the same 
cell at the identical frequency as command voltage after switching the amplifier to voltage-clamp 
mode. The current trace obtained under these conditions (Ibase) is a horizontal line positioned at the 
zero level except for the very short segment corresponding to the action potential upstroke. To isolate 
the 1st current of interest, its blocker was used to reveal it from the net membrane current (Idrug1). The 
profile of this current was determined by subtracting the post-drug curve from the pre-drug one 
(I1 = Ibase – Idrug1). It was followed by the isolation of the 2nd current of interest by applying the specific 
modulator of the 2nd current in the continuous presence of the first drug, and then the 2nd current was 
obtained by subtraction (I2 = Idrug1 – Idrug1+drug2). These currents were always recorded after the action of 
the applied agent reached steady-state. The following agents were used for dissecting the currents: 
0.5 mmol/L 9-AC for I9-AC, basically ICl(Ca), 1 µmol/L nisoldipine for INISO, consisting of ICa,L and the 
ion current flowing through Na+/Ca2+ exchanger as the two most important component. The following 
currents were studied and defined in APVC experiments as: 
I9-AC = I (measured prior to the application of 9-AC) – I (measured in the presence of 9-AC), 
INISO = I (measured in the presence of 9-AC) – I (measured in the presence of NISO+9-AC). 
Ion currents were normalized to cell capacitance, determined in each cell using hyperpolarizations 
from +10 to −10 mV for 15 ms. Cell capacitance was 129±6 pF in the average of the 85 myocytes 
studied. 
 
Measurement of intracellular Ca2+ concentration ([Ca2+]i) 
Myocytes were loaded in Tyrode solution with the membrane-permeant form of 5 µmol/L Fura-2 in 
the presence of Pluronic F-127 for 30 min at room temperature. A period of minimum 30 min was 
allowed for de-esterification of the dye at room temperature then cells were stored at 15 ºC until the 
experiment. Loaded cells were illuminated using a 40x oil immersion objective (CFI S-Fluor 40x oil, 
Nikon) or 40 x air objective (40UV/340, Olympus). Cells were excited with 340 and 380 nm light 
from a xenon arc lamp (Ushio Deutschland GmbH, Steinhöring, Germany). Excitatory wavelengths 
were altered by a dual-wavelength excitation monochromator and an on-line connected microcomputer 
(DeltaScan, Photon Technology International, New Brunswick, NJ, USA). Fluorescence emission was 
monitored at 510 nm using a R1527P photomultiplier tube (Hamamatsu Photonics Deutschland 
GmbH., Herrsching am Ammersee, Germany) at an acquisition rate of 200 Hz. Changes in 
intracellular free Ca2+ levels were approximated by the ratio of the fluorescence intensity obtained at 
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340 and 380 nm excitation after correction for nonspecific background fluorescence and recorded 
using FeliX32 Software & BryteBox Interface (Photon Technology International, New Brunswick, NJ, 
USA) and presented as F340/F380 on Figures. Ten consecutive [Ca2+]i transients were averaged and 
analyzed off-line. 
 
Single cell shortening measurements 
Myocyte contractions were recorded with a video-edge detector system (VED-105, Crescent 
Electronics, Sandy, Utah, USA) sampling at 240 Hz. Shortening of isolated cardiomyocytes was 
expressed as a percentage of diastolic cell length measured in control. The analogue signal of cell 
length was amplified (DC amplifier, Főnixcomp Ltd, Hungary), digitized (Digidata 1440A, Molecular 
Devices) and recorded using pClamp 10 software (Molecular Devices). During subsequent off-line 
analysis, 10 consecutive curves were averaged. 
 
Immunolabeling, confocal imaging and Western blotting 
Canine left ventricular myocytes were seeded into glass coverslips and kept at 37 °C for 2-3 hours. 
Living cells attached to the surface of the coverslips. Human left ventricular samples were embedded 
in Cryomatrix (Thermo Scientific, Rockford, IL, USA) and 10 µm thick sections were cut at −20°C 
using Shandon Cryotome E (Thermo Electron Corporation, Waltham, MA, USA). Sections were let to 
dry and the appropriate immunohistochemistry was performed. Immunolabeling was started with 
paraformaldehyde fixation (4 %, 15 min, 22 °C) of either isolated myocytes seeded into the glass 
coverslips or the frozen tissue sections. Following three times repeated washing (10 min, Phosphate 
Buffered Saline (PBS) or PBS-Tween20 containing 100 mmol/L glycine as a quenching agent), cells 
and tissue samples were permeabilized with Triton-X-100 (0.1 v/v%, 10 min, 22 °C) and then blocked 
with 1 or 4% BSA solution (30 min or 60 min, 22 °C, respectively). Cells were then probed with anti-
TMEM16A (Santa Cruz Biotechnology, Dallas, TX, USA, sc-135235; rabbit, 1:200), anti-Bestrophin-
3 (Santa Cruz Biotechnology, Dallas, TX, USA, sc-70147, goat, 1:200), anti-Cav1.2 (Santa Cruz 
Biotechnology, Dallas, TX, USA, sc-16229R, rabbit, 1:200), anti-ryanodine receptor (BD Biosciences, 
San Jose, CA, USA; mouse, 1:200), or with anti-cytochrome c (Santa Cruz Biotechnology, mouse, 
1:200) primary antibodies. These primary antibodies were used overnight in 1 % BSA solution at 4 °C. 
Isolated human cells were placed on glass microscope slides and fixed with ice cold acetone for 5 
minutes. Cells were rehydrated using 5% BSA solution for 2-3 hours and then washed with PBS (three 
times for 15 min at room temperature). In the case of isolated human cells and cryosections of human 
left ventricular tissues primary antibodies against TMEM16A, Bestrophin-3 and Cav1.2 protein were 
used in 1:100 dilution (in 1% BSA, 4°C, overnight). The procedure was continued with the appropriate 
secondary antibody labeling as follows: biotinylated anti-rabbit, anti-mouse or anti-goat antibody 
(Vector Laboratories, Burlingame, CA, USA, 1:300, 45 min, 22 °C) then Streptavidine Alexa488 (Life 
Technologies, Carlsbad, CA, USA; 1:100, 30 min, 22 °C) incubation and finally with Cy3 anti-mouse 
or anti-rabbit labeling (Vector Labs; 1:500, 60 min, 22 °C). The specific staining was tested by 
omitting the primary antibodies during the incubation procedure and also by Western blotting (see 
details below) and immunocytochemistry (Supplementary Fig. 2). To visualize the nuclei, cells were 
mounted with Vectashield mounting medium containing 4',6-diamidino-2-phenylindole (DAPI, Vector 
Labs.). Images were taken using Zeiss laser scanning confocal microscope (Zeiss LSM 510 Meta; 
using 488, 543 and 405 nm excitation wavelengths and 40x oil immersion objective). 
The Pearson correlation coefficient was used to quantify the degree of co-localization between 
fluorophores. A correlation between the intensities could reflect a direct or indirect molecular 
interaction. All analysis and image processing was performed using Zeiss LSM510 Software. 
Total cell lysates isolated from canine left ventricular cardiomyocytes were prepared and used for 
Western blot experiments. Samples were subjected to SDS-PAGE (7.5 % gels loaded with 40 µg 
protein per lane) and transferred to nitrocellulose membranes (Bio-Rad). The nitrocellulose-bound 
proteins were then blocked with 5 % dry milk in phosphate-buffered saline (PBS; pH 7.4) and probed 
with anti-TMEM16A primary antibodies followed by the appropriate HRP-conjugated secondary 
antibody labeling. The immunoreactive bands were visualised using an enhanced chemiluminescence 
Western blotting Pico or Femto detection kit (Thermo Scientific, Rockford, IL, USA) in a Fujifilm 
Labs-3000 dark box. 
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Specificity of the used antibodies 
 
TMEM16A 
To test the specificity of anti-TMEM16A antibody we performed Western blot experiments on canine 
left ventricular myocytes and human left ventricular tissue samples. In all cases a strong and solid 
single band could be detected (Supplementary Fig. 2A). The molecular weight however was lower 
than the predicted 114 kDa appearing consistently between 70 and 110 kDa and closer to the former. It 
is not unusual that an antibody detects a band having different molecular weight than the predicted one 
so even the manufacturers sometimes mention this in their specifications. This is the case for instance 
with anti-TMEM16A antibodies SAB2102460 and SAB3500318 as bands were observed at 90 and 72 
kDa, respectively. Also, with TMEM16A antibody (ab84115) the band appeared at 90 kDa instead of 
the predicted 114 kDa (http://www.abcam.com/tmem16a-antibody-ab84115.html). According to the 
manufacturer possible reasons for the difference include: post-translational modification, post-
translation cleavage, splice variants, relative charge and multimers (e.g. dimerisation of a protein). 
This last one is usually prevented in reducing conditions, although strong interactions can result in the 
appearance of higher bands. The molecular weight of the protein band detected by anti-TMEM16A 
antibody (ab53213) used in the publication of Davis et al. showed tissue specificity as in murine portal 
vein it was below 80 kDa instead of the predicted size of 114 kDa which was the case for murine 
thoracic aorta and carotid artery [6]. Moreover, on murine portal vein samples the same antibody 
detected TMEM16A at around 160 kDa in a study of the same research group [7]. Exactly the same 
antibody however detected Ano1 at 149 and 139 kDa when used in brain and uterinal smooth muscle 
samples from mouse and human origin, respectively [8]. From these publications it seems that even 
the exactly same antibody can detect TMEM16A at different molecular weights on samples of various 
origin and even on the same tissues. 
It must be highlighted that the antibodies used in our experiments were produced against human 
proteins which can be different from that of canine not only in sequence but also in molecular weight. 
According to our knowledge there are no publications made on canine cells/tissue describing the 
expression and molecular weight of either TMEM16A or Bestrophin-3. This interspecies difference 
however is unlikely as there were no major difference between molecular weights where TMEM16A 
was detected in human and canine tissues. 
One explanation for the lower molecular weight can be isoform variations as for human TMEM16A 
three isoforms are known with molecular weights of 114, 98 and 74 kDa 
(http://www.uniprot.org/uniprot/Q5XXA6). The molecular weight of canine TMEM16A is 106 kDa 
(http://www.uniprot.org/uniprot/F1PQF9). Alternative splicing of TMEM16A has been reported 
previously in many tissues including the heart [9,10]. 
The TMEM16A antibody (H-41): Santa Cruz, sc-135235, used in our study recognizes a sequence that 
is present in each of the three isoforms, hence it is able to detect all of them. The band appeared in our 
experiments with TMEM16A antibody was lower than the predicted size of 114 kDa therefore it is 
unlikely that dimer formation of TMEM16A could occur. Nevertheless, not only homo- but also 
heterodimer formation of various TMEM16A isoforms was observed in murine portal vein [11]. 
 
Bestrophin-3 
To test the specificity of anti-Bestrophin-3 antibody we performed Western blot experiments on 
canine left ventricular myocytes and human left ventricular tissue samples. As mentioned with 
TMEM16A, antibodies designed to recognize Bestrophin-3 can signal bands with other than the 
predicted molecular weight as for antibodies ab94904, Proteintech 20443-1-AP and ab123887. 
Regarding human Bestrophin-3 five isoforms has been described 
(http://www.uniprot.org/uniprot/Q8N1M1) but only four has been predicted in canine according to 
NCBI protein database. The five human isoforms have molecular weights of 76, 46, 8, 51 and 63 kDa. 
The shorter isoforms differ from the longest due to the lack of one or more parts of the full sequence. 
The antibody used in our experiments (Bestrophin-3 antibody (T-16): Santa Cruz, sc-70147, molecular 
weight: 47 kDa) recognizes and targets a sequence within a cytoplasmic domain but it is not specified 
where. According to our Western blots the bands between 100 and 130 kDa and 35 and 55 kDa were 
absent in the presence of the blocking peptide (not shown). The smaller size band is in the range of the 
size indicated by the manufacturer (47 kDa) and the antibody can bind to both the 46 and 51 kDa 
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isoforms. A possibility for the occurrence of Bestrophin-3 signal between 100 and 130 kDa on our 
Western blots is oligomerisation. Indeed, Bestrophins have been predicted to form dimers, tetramers or 
pentamers [12, 13] and Bestrophin-3 homodimer formation was confirmed [14]. The processing of 
samples (application of reducing conditions) can however destroy these oligomers and separate 
subunits from each other but strong interactions between isoforms or various proteins might remain 
intact. 
To show the specificity of Bestrophin-3 antibody, parallel experiments were conducted using 
immunolabeling in the presence or the absence of the blocking peptide with exactly the same 
recording settings (gain, time of acquisition, pixel size etc…) during confocal imaging (Supplementary 
Fig. 2B). Only those isolated canine left ventricular myocytes cells showed striated pattern of green 
fluorescence (suggesting the presence of Bestrophin-3), where the specific blocking peptide was not 
used during the procedure. Those cells, however, where Bestrophin-3 antibody was used together with 
the blocking peptide during the procedure show barely detectable green color and only blue DAPI 
staining of nuclei was visible. 
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Table 1 
I9-AC peaks measured by APVC under various experimental conditions 
Condition Early outward peak (A/F) Late inward peak (A/F) n  
Control chloride, 1 Hz 
(47 mmol/L [Cl−]pipette) 
1.62±0.08 −0.16±0.03 15 
Control chloride, 1 Hz 
10 mmol/L EGTA in pipette 
1.17±0.09 −0.13±0.02 9 
Control chloride, 1 Hz 
10 mmol/L BAPTA in pipette 
0.13±0.10 −0.08±0.02 6 
    
Low chloride, 1 Hz 
(27 mmol/L [Cl−]pipette) 
2.44±0.27 −0.06±0.03 4 
 
Control chloride, 1 Hz 1.67±0.12 −0.12±0.02 5 
Control chloride, 2 Hz 2.07±0.19 −0.15±0.02 5 
 
Control chloride, 1 Hz 
10 nmol/L isoproterenol 
3.10±0.21 −0.36±0.11 6 
Control chloride, 1 Hz 
20 nmol/L Bay K8644 
2.86±0.15 −0.30±0.03 8 
Control chloride, 1 Hz 
10 µmol/L ryanodine 
1.05±0.03 −0.07±0.03 4 
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Supplementary Fig. 1 Temporal alignment of I9-AC and INISO measured with sequential APVC. 
Representative membrane potential (A) and current traces (B) measured on the same cell showing the 
first 15 ms of the AP. During the experiment the application of 9-AC was followed by the application 
of nisoldipine. I9-AC (0.5 mmol/L 9-AC-sensitive current) is illustrated with blue while INISO trace 
(1 µmol/L nisoldipine-sensitive current, including ICa,L and Na+/Ca2+ exchange current as two main 
components) is shown in red. Vertical dashed lines are placed at the peak of the AP (line 1), inward 
peak of INISO (line 2), outward peak of I9-AC (line 3) and at the end of phase-1 repolarization (line 4). 
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Supplementary Fig. 2 Specificity of antibodies used to detect TMEM16A and Bestrophin-3 proteins. 
(A) Representative full length Western blot image made with the primary antibody against TMEM16A 
(Santa Cruz Biotechnology, sc-135235, predicted molecular weight: 114 kDa.). Lanes 1-6 are isolated 
ventricular myocytes obtained from various layers of two canine left ventricles. 
(B) Images taken from four canine left ventricular cells using exactly the same recording settings 
(gain, time of acquisition, pixel size etc…) during confocal imaging in the presence (upper four 
images) or the absence (lower two images) of the blocking peptide (Santa Cruz Biotechnology, sc-
70147-P) against the Bestrophin-3 antibody (Santa Cruz Biotechnology, sc-70147). Left images in the 
upper pairs show the two cells using transmitted light of the confocal microscope and the right ones 
show nuclear staining in blue and very weak Bestrophin-3 staining (in green color) on the same cells. 
On the lowest two images, obtained without using the blocking peptide, striated labeling pattern can 
be observed. 
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TMEM16A (red) + Bestrophin-3 (green) + nuclei (blue) + Merged
Cav1.2 (red) + Bestrophin-3 (green) + nuclei (blue) + Merged
A
B
 
Supplementary Fig. 3 Confocal images showing the expression pattern of Cav1.2, TMEM16A, and 
Bestrophin-3 in canine ventricular myocytes. 
(A) Expression of Cav1.2, Bestrophin-3, and nuclear staining in red (upper left), green (upper right), 
and blue (lower left), respectively. The lower right panel represents the overlay of the three images. 
Images depict approximately the upper 20 % of the cell presented on Fig. 7A. 
(B) Expression of TMEM16A, Bestrophin-3, and nuclear staining in red (upper left), green (upper 
right), and blue (lower left), respectively. The lower right panel represents the overlay of the three 
images. Images show approximately the lower 25 % of the cell presented on Fig. 7B. 
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Supplementary Fig. 4 Expression patterns of TMEM16A, Bestrophin-3, RyR and cytochrome c in 
canine ventricular myocytes. 
(A) Representative cell showing the expression of cytochrome c, TMEM16A, and nuclear staining in 
red, green, and blue, respectively, from left to right. The far right panel represents the overlay of the 
three images. 
(B) Representative cell showing the expression of RyR, Bestrophin-3, and nuclear staining in red, 
green, and blue, respectively from left to right and the overlay of these three images. Enlarged images 
made from the upper half of the same cell are represented on the right side. 
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Supplementary Fig. 5 Confocal images showing the expression pattern of Cav1.2, TMEM16A, and 
Bestrophin-3 in non-diseased human left ventricular tissues. 
(A) Representative images showing the expression of Cav1.2, Bestrophin-3, and nuclear staining in red 
(upper left), green (upper right), and blue (lower left), respectively. The lower right panel represents 
the overlay of the three images and enlarged on the right. White arrows point to some striations. 
(B) Representative image showing the expression of TMEM16A, Bestrophin-3, and nuclear staining in 
red (upper left), green (upper right), and blue (lower left), respectively. The lower right panel 
represents the overlay of the three images and enlarged on the right. White arrows point to some 
striations. 
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